Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: A systematic review

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 775-785

  Ligthart, Suzanne A ^a   van Charante, Eric P Moll ^a   van Gool, Willem A ^a   Richard, Edo ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cardiovascular risk factors; Cognitive decline; Dementia; Prevention

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOLIC ACID; GLICLAZIDE; HOMOCYSTEINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INSULIN; METFORMIN; NITRENDIPINE; PERINDOPRIL; PLACEBO; PRAVASTATIN; PYRIDOXINE; RESERPINE; RIBOFLAVIN; SIMVASTATIN; UNINDEXED DRUG; VITAMIN B GROUP;

ADD ON THERAPY; AGED; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; COGNITIVE DEFECT; DEMENTIA; DRUG MEGADOSE; DYSLIPIDEMIA; FOLLOW UP; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; REVIEW; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; MIDDLE AGED; RISK MANAGEMENT; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR DISEASES; COGNITION DISORDERS; DEMENTIA; DIABETES MELLITUS; DYSLIPIDEMIAS; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MIDDLE AGED; OBESITY; RISK MANAGEMENT; TREATMENT OUTCOME;

EID: 78649313347     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S7343     Document Type: Review

References (58)

1. Fratiglioni LM, Launer LJP, Andersen KM, et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology. 2000;54:S10-S15.
2. Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? Neurology. 2009;72:368-374.
3. Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P. Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med. 2009;6:e1000180.
4. Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia. N Engl J Med. 2009;360:2302-2309.
5. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197-2204.
6. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer Disease: the Nun Study. JAMA. 1997;277:813-817.
7. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222.
8. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer Disease and decline in cognitive function. Arch Neurol. 2004;61:661-666.
9. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med. 2003;163:1524-1528.
10. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006;5:735-741.
11. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's Disease. N Engl J Med. 2002;346:476-483.
12. Skoog I, Nilsson L, Persson G, et al. A 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141-1145.
13. Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol. 1999;56:991-996.
14. Khachaturian AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer Disease: The Cache County Study. Arch Neurol. 2006;63:686-692.
15. Luchsinger JA, Tang MX, Miller J, Green R, Mayeux R. Relation of higher folate intake to lower risk of Alzheimer Disease in the elderly. Arch Neurol. 2007;64:86-92.
16. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223-227.
17. Richard E, Gouw AA, Scheltens P, van Gool WA. Vascular care in patients with Alzheimer Disease with cerebrovascular lesions slows progression of white matter lesions on MRI. The Evaluation of Vascular Care in Alzheimer's Disease (EVA) Study. Stroke. 2010; STROKEAHA.
18. Fogari R, Mugellini A, Zoppi A, et al. Effect of telmisartan//hydrochlorothiazide vs lisinopril//hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens. 2005;20:177-185.
19. Goldstein G, Materson BJ, Cushman WC, et al. Treatment of hypertension in the elderly: II. Cognitive and behavioral function. Results of a Department of Veterans Affairs Cooperative Study. Hypertension. 1990;15:361-369.
20. UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care. 1999;22:1125-1136.
21. Naor M, Steingrber HJ, Westhoff K, Schottenfeld-Naor Y, Gries AF. Cognitive function in elderly non-insulin-dependent diabetic patients before and after inpatient treatment for metabolic control. J Diabetes Complicat. 2001;11:40-46.
22. Ryan CM, Freed MI, Rood JA, Cobitz AR, Waterhouse BR, Strachan MW. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care. 2006;29:345-351.
23. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA. 1998;280:1490-1496.
24. Wolters M, Hickstein M, Flintermann A, Tewes U, Hahn A. Cognitive performance in relation to vitamin status in healthy elderly German women - the effect of 6-month multivitamin supplementation. Preventive Med. 2005;41:253-259.
25. Eussen SJ, de Groot LC, Joosten LW, et al. Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial. Am J Clin Nutr. 2006;84:361-370.
26. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
27. Di Bari M, Pahor M, Franse LV, et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial. Am J Epidemiol. 2001;153:72-78.
28. Prince MJ, Bird AS, Blizard RA, Mann AH. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults. BMJ. 1996;312:801-805.
29. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-1351.
30. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162:2046-2052.
31. Tzourio C, Anderson C, Chapmen N, et al. The PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069-1075.
32. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886.
33. Saxby BKB, Harrington FM, Wesnes KAP, McKeith IGM, Ford GAM. Candesartan and cognitive decline in older patients with hypertension: A substudy of the SCOPE trial. Neurology. 2008;70:1858-1866.
34. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7:683-689.
35. Douma S, Petidis K, Zamboulis C, Messerli FH, Sulicka J, Gryglewska K, et al. Treatment of hypertension in the elderly. N Engl J Med. 2008;359:971-974.
36. McGuinness B, Todd S, Passmore AP, Bullock R. Systematic review: Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. J Neurol Neurosurg Psychiatry. 2008;79:4-5.
37. Heart Protection Study collaborative group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360:7-22.
38. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
39. Packard CJ, Westendorp RG, Stott DJ, et al. Association between apolipoprotein E4 and cognitive decline in elderly adults. J Am Geriatr Soc. 2007;55:1777-1785.
40. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2009;2:CD003160.
41. Trompet S, van Vliet P, de Craen AJM, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol. 2010;257:85-90.
42. Stott DJ, MacIntosh G, Lowe GD, et al. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. Am J Clin Nutr. 2005;82:1320-1326.
43. Kang JH, Cook N, Manson J, Buring JE, Albert CM, Grodstein F. A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease. Am J Clin Nutr. 2008;88:1602-1610.
44. Viswanathan AM, Raj S, Greenberg SMM, et al. Plasma A[beta], homocysteine, and cognition: The Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology. 2009;72:268-272.
45. Brady CB, Gaziano JM, Cxypoliski RA, et al. Homocysteine lowering and cognition in CKD: The Veterans Affairs Homocysteine Study. Am J Kidney Dis. 2009;54:440-449.
46. Durga J, van Boxtel MP, Schouten EG, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet. 2007;369:208-216.
47. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med. 2006;354:2764-2772.
48. Cukierman T, Gerstein H, Williamson J. Cognitive decline and dementia in diabetes - Çösystematic overview of prospective observational studies. Diabetologia. 2005;48:2460-2469.
49. Malouf R, Grimley EJ. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev. 2008;4:CD004514.
50. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
51. Williamson JD, Miller ME, Bryan RN, et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORDMIND): rationale, design, and methods. Am J Cardiol. 2007;99: S112-S122.
52. Grimley Evans J, Areosa Sastre A. Effect of the treatment of type II diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev. 2003;1:DOI: 10.1002/14651858.CD003804.
53. Strandberg TE, Pitkala KH, Berglind S, Nieminen MS, Tilvis RS. Multifactorial intervention to prevent recurrent cardiovascular events in patients 75 years or older: The Drugs and Evidence-Based Medicine in the Elderly (DEBATE) study: a randomized, controlled trial. Am Heart J. 2006;152:585-592.
54. Beiser A, D'Agostino RB, Seshadri S, Sullivan LM, Wolf PA. Computing estimates of incidence, including lifetime risk: Alzheimer's disease in the Framingham Study. The Practical Incidence Estimators (PIE) macro. Stat Med. 2000;19:1495-1522.
55. Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 1997;349:151-154.
56. Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465.
57. Richard E, Van den Heuvel E, Moll van Charante E, et al. Prevention of Dementia by Intensive Vascular Care (PreDIVA): a cluster-randomized trial in progress. Alzheimer Dis Assoc Disord. 2009.
58. Ahtiluoto S, Rauramaa R, Soininen H, et al. Scandinavian multi-domain interventions to delay cognitive impairment. Abstract. Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) Jul 2009, Vienna, Austria.